CDK1/2/4-IN-1 (compound 3a) (0.01-100 μM; 24 hours) has antitumor activity in cancer cell lines [1]. CDK1/2/4-IN-1 (compound 3a) (1.39 μM; 24 hours) induces apoptosis and arrests cell cycle at G2/M phase in A549 cells [1]. CDK1/2/4-IN-1 (compound 3a) (1.39 μM; A549 cells) induces up-regulation of the expression of Bax, caspases-3 and p53, and increases the ratio of Bcl-2 [1]. Cell Cytotoxicity Assay [1] Cell Line: Liver cancer cell line (HepG-2), lung cancer cell line (A549) and breast cancer cell line (MCF-7) Concentration: 0.01, 0.1, 1.0, 10, 100 μM Incubation Time: 24 hours Result: Displayed cytotoxic activity with IC 50 values of 1.56, 1.39 and 1.97 μM for HepG-2, A549 and MCF-7, respectively. Cell Cycle Analysis [1] Cell Line: A549 cells Concentration: 1.39 μM Incubation Time: 24 hours Result: Increased G2/M phase by 2.6 folds compared with the control cells. Apoptosis Analysis [1] Cell Line: A549 cells Concentration: 1.39 μM Incubation Time: 24 hours Result: Increased the overall percentage of the apoptotic cells.